Spero Therapeutics, Inc. (SPRO)
1.11
-0.02
(-1.77%)
USD |
NASDAQ |
Oct 23, 16:00
1.11
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Enterprise Value : 15.81M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 15.81M |
| October 22, 2026 | 16.98M |
| October 21, 2026 | 19.30M |
| October 20, 2026 | 22.21M |
| October 19, 2026 | 16.39M |
| October 16, 2026 | 15.23M |
| October 15, 2026 | 16.98M |
| October 14, 2026 | 16.39M |
| October 13, 2026 | 18.14M |
| October 12, 2026 | 19.88M |
| October 09, 2026 | 21.05M |
| October 08, 2026 | 17.56M |
| October 07, 2026 | 19.30M |
| October 06, 2026 | 20.46M |
| October 05, 2026 | 18.72M |
| October 02, 2026 | 20.46M |
| October 01, 2026 | 24.53M |
| September 30, 2026 | 21.63M |
| September 29, 2026 | 21.05M |
| September 28, 2026 | 20.46M |
| September 25, 2026 | 22.79M |
| September 24, 2026 | 23.95M |
| September 23, 2026 | 24.53M |
| September 22, 2026 | 30.35M |
| September 21, 2026 | 17.56M |
| Date | Value |
|---|---|
| September 18, 2026 | 16.98M |
| September 17, 2026 | 16.39M |
| September 16, 2026 | 15.81M |
| September 15, 2026 | 16.98M |
| September 14, 2026 | 17.56M |
| September 11, 2026 | 16.98M |
| September 10, 2026 | 16.39M |
| September 09, 2026 | 19.30M |
| September 08, 2026 | 20.46M |
| September 04, 2026 | 21.63M |
| September 03, 2026 | 22.21M |
| September 02, 2026 | 22.21M |
| September 01, 2026 | 21.05M |
| August 31, 2026 | 22.21M |
| August 28, 2026 | 21.05M |
| August 27, 2026 | 21.63M |
| August 26, 2026 | 22.21M |
| August 25, 2026 | 22.79M |
| August 24, 2026 | 21.92M |
| August 21, 2026 | 22.21M |
| August 20, 2026 | 21.63M |
| August 19, 2026 | 22.79M |
| August 18, 2026 | 21.05M |
| August 17, 2026 | 20.46M |
| August 14, 2026 | 22.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 45.20M |
| Fortress Biotech, Inc. | -37.02M |
| Kura Oncology, Inc. | 360.28M |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.552M |
| Total Expenses (Quarterly) | 9.552M |
| EPS Diluted (Quarterly) | -0.1648 |
| Earnings Yield | 9.83% |
| Operating Earnings Yield | 4.02% |
| Normalized Earnings Yield | 10.50 |